Applied DNA Ships LinearDNA™ to Another Development Customer
March 26 2020 - 8:37AM
Business Wire
- Subsidiary
of Global Biopharmaceutical Company to Evaluate Linear DNA as
Replacement for Plasmids for CAR T Applications -
Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the
“Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA
manufacturing that enables diagnostics, pre-clinical nucleic
acid-based therapeutic drug candidates, supply chain security,
anti-counterfeiting and anti-theft technology, announced today that
it has shipped two CAR T amplicons proprietary to the biologics
subsidiary of a U.S.-based, global biopharmaceutical company. The
customer is one of nearly two dozen development customers in
various stages of evaluating the use of linear DNA manufactured by
the Company.
“We see a steady flow of interest for our LinearDNA™
manufacturing platform from customers with gene and redirected-cell
therapies. Securing development customers is the first step in our
LinearDNA commercialization strategy that offers a path to higher
and recurring revenues as customers validate linear DNA as a viable
alternative to plasmid DNA. We expect some customers will license
our intellectual property to enable the optimal performance of
their therapeutic,” said Dr. James Hayward, president and CEO of
Applied DNA. “I am especially proud of our team during this
coronavirus outbreak who continue to prioritize our work on
COVID-19-related therapies and diagnostics, as well as deliver
linear DNA to customers without interruption. In the coming weeks
and months, we expect to continue our work with all therapeutic
customers to optimize LinearDNA for their unique therapeutic
applications.”
LinearDNA™ is Applied DNA’s branded platform for large-scale DNA
manufacture by PCR.
About Applied DNA Sciences, Inc.
Applied DNA is a provider of nucleic acid technologies that
enable diagnostics, pre-clinical nucleic acid-based therapeutic
drug candidates, supply chain security, anti-counterfeiting
anti-theft technology and product genotyping.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list. Common stock listed on NASDAQ
under the symbol APDN.
LinearDNA™ is a trademark of Applied DNA Sciences, Inc
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934 and the Private Securities Litigation Reform Act of
1995. Forward-looking statements describe Applied DNA’s future
plans, projections, strategies and expectations, and are based on
assumptions and involve a number of risks and uncertainties, many
of which are beyond the control of Applied DNA. Actual results
could differ materially from those projected due to the possibility
of a failure to make timely payment on its outstanding secured
convertible notes and resulting enforcement by noteholders of
remedies on collateral which includes substantially all of Applied
DNA’s assets, its history of net losses, limited financial
resources, limited market acceptance, the fact that there has never
been a commercial drug product utilizing PCR-produced DNA
technology approved for therapeutic use, the uncertainties inherent
in research and development, future clinical data and analysis,
including whether any of Applied DNA’s or its partners product
candidates will advance further in the preclinical research or
clinical trial process, including receiving clearance from the U.S.
Food and Drug Administration or equivalent foreign regulatory
agencies to conduct clinical trials and whether and when, if at
all, they will receive final approval from the U.S. FDA or
equivalent foreign regulatory agencies, the unknown outcome of any
applications to U.S. FDA or equivalent foreign regulatory agencies,
Applied DNA’s ability to obtain and maintain adequate protection
for intellectual property rights relating to its product candidates
and technologies, and various other factors detailed from time to
time in Applied DNA’s SEC reports and filings, including our Annual
Report on Form 10-K filed on December 12, 2019 and our subsequent
quarterly report on Form 10-Q filed on February 6, 2020, and other
reports we file with the SEC, which are available at www.sec.gov.
Applied DNA undertakes no obligation to update publicly any
forward-looking statements to reflect new information, events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events, unless otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200326005345/en/
investor contact: Sanjay M. Hurry, LHA Investor
Relations, 212-838-3777, shurry@lhai.com program contact:
Brian Viscount, Applied DNA, 631-240-8877, brian.viscount@adnas.com
web: www.adnas.com, www.adnas.com/linearx twitter:
@APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024